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Background—Cardiovascular disease is the leading cause of increased mortality for adolescents
with advanced kidney disease. The quality of preventive cardiovascular care may impact long-
term outcomes for these patients.
Methods—We reviewed records of 196 consecutive adolescents from 8 centers with pre-dialysis
chronic kidney disease, on dialysis, or with a kidney transplant who transferred to adult-focused
providers. We compared cardiovascular risk assessment and therapy within and across centers.
Predictors of care were assessed using multilevel models.
Results—Overall, 58% (range: 44%–86%, p=0.08 for variance) of five recommended
cardiovascular risk assessments were documented. Recommended therapy for six modifiable
cardiovascular risk-factors was documented 57% (26%–76%, p=0.09) of the time. Thirty-percent
of patients (n=59) were reported to go through formal transition which was independently
associated with a 21% increase in composite cardiovascular risk assessment (p<0.001). Transfer
after 2006 and kidney transplant status were also associated with increased cardiovascular risk
assessment (p<0.01 and p=0.045, respectively).
Conclusions—Adolescents with kidney disease receive sub-optimal preventive cardiovascular
care, which may contribute to their high risk of future cardiovascular mortality. Great opportunity
exists to improve outcomes for children with kidney disease by improving reliability of preventive
care that may include formal transition programs.
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Cardiovascular disease; transition; quality; chronic kidney disease; kidney transplantation; dialysis
Introduction
Outcomes for children with chronic kidney disease (CKD) and end-stage renal disease
(ESRD) have improved with an increasing number surviving well into adulthood.[1–2]
Unfortunately, many of these patients have cardiovascular disease (CVD) mortality rates
over 1,000 times that of their age-matched peers and will experience premature death due to
CVD in early adulthood.[3–4] This exceedingly high CVD risk is related to a high
prevalence of traditional cardiovascular risk factors (CVRFs) that predict CVD in the
general population (such as hypertension, dyslipidemia, obesity, diabetes, and smoking) in
addition to other non-traditional CVRFs that increase in prevalence with decreased kidney
function (such as chronic inflammation, oxidative stress, abnormal mineral metabolism,
hyperhomocysteinemia, endothelial dysfunction, increased burden of coronary calcification
and treatment with steroids and/or calcineurin inhibitors).[5–6] Accordingly, guidelines
published as early as 2003 recommend screening for, and strict control of modifiable
CVRFs in these patients.[5–13] Recent publications have highlighted the suboptimal quality
of care for children with chronic illnesses in the primary care setting,[14] and for adults with
CKD[15] or a kidney transplant (TXP),[16] yet little is known regarding the patterns of care
for adolescents with kidney disease in relation to published guidelines.
Because of a standardized approach and focus on adult-specific issues, formal transition
programs have been advocated as a means to improve care for adolescents transferring to
adult-focused providers1, 14–17 and may improve preventive CVD care for young adults with
kidney disease. Herein we report our findings regarding the patterns of preventive
cardiovascular care in such patients. We hypothesized that patterns of care would be more
likely related to center-specific practice patterns than individual patient characteristics, and
that patients reported to go through formal transition programs would receive more reliable
assessment and treatment of modifiable CVRFs.
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After obtaining Institutional Review Board approval at eight participating pediatric
nephrology centers from the Midwest Pediatric Nephrology Consortium (United States and
Canada), we systematically reviewed charts of consecutive patients with CKD, ESRD on
dialysis, or TXP during childhood who transferred care to an adult-focused provider
between January 1, 1997 and June 30, 2009.
Selection of Measures and Evidence Base
To assess quality of CVD care, we evaluated three domains of measures: 1) recommended
CVRF assessment, 2) prevalence of modifiable CVRFs and 3) recommended therapy for
those with modifiable CVRFs. Several international guidelines exist for CVD management
in adolescents with kidney disease.[5–13, 17] The measures evaluated in this study were
selected from the most comprehensive guideline published at the time by Kavey et al. in
2006.[6] More recent guidelines make similar but even more detailed and specific
recommendations.[17] While recommendations are based primarily on observational data in
children or extrapolation of interventional trials in adults, given the substantial evidence
regarding the early onset of atherosclerosis in childhood in high-risk populations[18], such
recommendations are based on the best available evidence. In addition, even though some
literature suggests an inverse relationship between traditional CVRF’s and mortality in adult
dialysis patients[19–20] (in contrast to those with CKD or TXP), no such data exists for
children or adolescents.
Consequently, guidelines from the American Heart Association,[6] National Kidney
Foundation,[11–12] and the National Heart, Lung, and Blood Institute,[17] recommend
treating adolescents on dialysis similar to those with a kidney transplant and/or CKD. Thus,
we applied these guidelines to each of the three populations (ESRD, CKD, TXP). Finally,
while multiple non-traditional CVRF’s (e.g. inflammation, oxidative stress, abnormal
mineral metabolism, hyperhomocysteinemia, etc.) affect the cardiovascular outcomes in
patients with kidney disease, we chose to focus this report on assessment and treatment of
traditional CVRF’s that have been widely adopted into guidelines specific to adolescents.
Measures and Definitions
To evaluate CVRF screening, we assessed whether documentation was present for each of
five CVRFs recommended by published guidelines[6, 10–12] including: family history of
CVD, smoking status, lipid profile, physical activity, and echocardiography for patients with
a history of hypertension. If values were missing for any CVD risk assessment in the entire
medical record, we assumed that assessment had not occurred.
We determined the prevalence of six modifiable CVRFs among patients assessed.
Dichotomous variables were created for smoking status (yes/no), history of elevated blood
pressure (blood pressure >90th percentile for age, gender, height or >130/80 for patients ≥ 18
years old), left ventricular hypertrophy as defined by each center based on
echocardiography, dyslipidemia (total cholesterol >200 mg/dl and/or low-density lipoprotein
cholesterol [LDL] >130 mg/dl), glucose intolerance (fasting glucose >100 mg/dl), and
obesity (body mass index [BMI] > 30kg/m2).
To evaluate treatment for modifiable CVRFs, we determined whether recommended therapy
was documented for each of the above CVRFs according to the following guideline
definitions:[5–6, 10, 12] 1) dietary consultation for any patient with at least one modifiable
CVRF or ESRD, 2) smoking cessation counseling for smokers 3) medication prescribed for
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elevated blood pressure, 4) medication prescribed for elevated cholesterol, 5) endocrine
referral for patients with elevated fasting glucose, 6) a formal exercise program and/or
referral to obesity clinic for those with obesity. Data were missing in approximately 5%
(24/478) of instances where therapy was indicated, preventing a determination of whether or
not therapy was prescribed. Accordingly, these instances were excluded.
We developed composite and all or nothing measures for CVRF assessment and therapy.
For composite measures we divided the number of assessments or therapies documented by
the number of assessments or therapies recommended. This metric thus reflects the
percentage of recommended care that was documented. For the all-or nothing measures, we
determined the percentage of patients with 100% of recommended care documented in the
medical record.
To assess patterns of transitional care, we recorded whether centers reported that a given
patient went through a formal transition program (defined by the presence of clinic policies
or tools that facilitate the transition process). While recent guidelines[21] recommend
specific essential components of effective transition programs, little documentation existed
over the period of this study. Thus, for this analysis, formal transition was defined for each
patient according to the above definition.
Statistical Methods
We generated descriptive statistics for continuous data using means with standard deviations
(normally distributed data) or medians with inter-quartile ranges (non-normal data). We
described categorical data with frequencies.
To compare group differences in demographics and CVRFs we used chi-squared
comparisons for categorical variables. For normally distributed continuous variables, we
used t-tests. For non-normal variables, we performed a square root transformation to
normalize the data prior to applying the t-test. For these analyses, we used techniques (e.g.,
Taylor-linearized variance estimation) that account for the clustered nature of the data
(patients nested within study centers).
To analyze composite CVD care, we used a multilevel model approach. Multilevel models
allowed us to include patient-level variables (e.g., race/ethnicity), and center-level variables
(e.g., presence of a formal transition program) simultaneously. This allowed us to assess
whether factors associated with a center predicted patient-level outcomes, as well as
partition the total variance in outcomes into variation due to center characteristics (as
quantified by the variance across centers) and variation due to patient characteristics.
Moreover, multilevel models appropriately account for the clustered nature of the data
(patients within centers) allowing for appropriate statistical inferences. In each of our
multilevel models, we allowed intercepts to vary randomly across centers. Our primary
outcome was the composite measure for CVRF assessment. Secondary outcomes included
the composite measure of therapy for modifiable CVRFs and each recommended assessment
and therapy individually. Patient-level predictors included whether each patient was reported
to go through a formal transition process, race and ethnicity, gender, disease population
(CKD, ESRD, TXP), insurance (private or public), and year of transfer (before 2006 vs.
2006 or later when the most comprehensive guideline was published.)[6] We performed a
multi-step analysis starting with bivariate analyses of each patient-level predictor. We then
developed a multivariable prediction model for each outcome that included important
patient-level predictors and covariates from our bivariate analyses. We estimated variances
for the outcomes by center. We treated our primary outcome for CVRF assessment as a
continuous variable and we report estimates for the average percent increase in documented
care with 95% confidence intervals (95% CI) for each patient level predictor. For
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dichotomous outcomes, we report adjusted odds ratios and 95% CI’s. We used STATA®
(StataCorp. 2010, Stata Statistical Software: Release 11; StataCorp LP, College Station, TX,
USA) to develop our models and considered p-values < 0.05 statistically significant.
Results
Patient Demographics and Transition
One-hundred ninety six patients (ESRD= 42, CKD=68, TXP=86,) from eight North
American pediatric centers were enrolled in the study (7 in the United States, 1 in Canada;
Table 1). Each center contributed 17–32 patients (median 25). Fifty-nine (30%) of 196
patients were reported to go through a formal transition, although this varied across centers
from 0% to nearly 90% (Figure 1, p = 0.057). TXP patients were older at transfer than
ESRD patients (median 20.6 vs. 19.2 years respectively, p=0.018). Patients who went
through a formal transition pathway were older at transfer (median 20.5 vs. 19.4 years,
p<0.001) and were more likely to transfer after 2006 (75% vs. 36%, p <0.001).
CVRF Assessment and Prevalence
Among five CVFRs studied (Figure 2, Table 2), smoking assessment was documented most
commonly (74%). An echocardiogram was documented in 70% of patients with a history of
hypertension and family history of CVD was documented in 53% of all patients. Fasting
lipid profiles (47%) and physical activity (47%) were assessed in fewer than half of patients.
Assessment of individual CVRFs varied moderately by center, as did the composite of
CVRF assessment (Table 2; mean 57%; range 44–86%; p=0.08). Overall, 58% of indicated
assessments were documented in the medical record, however, only 20/196 (10%) patients
received 100% of all indicated CVRF assessments.
The prevalence of CVRFs among those who were assessed was substantial (Table 3). Nearly
four-in-five had a history of hypertension and more than one-third of these had left
ventricular hypertrophy. More than one-quarter had dyslipidemia and a similar number had
elevated fasting glucose. Twenty-two percent were obese and 18% had a history of smoking.
Prevalence of CVRFs was generally similar across groups (Table 3). However, hypertension
was more common among ESRD and TXP patients than those with CKD (p=0.02) while
elevated LDL was more common among ESRD patients (p<0.01). Patients reported to go
through a formal transition pathway were less likely to have a family history of CVD
(p<0.01) and more likely to have an elevated fasting glucose (p<0.01).
Therapy for Modifiable CVRFs
Among the modifiable CVRFs, hypertension was the most likely to be treated (81%; Table
2), followed by dietary therapy from a dietician for any modifiable CVRF or ESRD (71%).
Therapy for other modifiable CVRF’s varied (Table 2). Overall, 57% of recommended
therapies were documented, though only 27% of patients (47/177) who had ≥1 modifiable
CVRF received 100% of recommended therapy. Composite CVD therapy varied modestly
by center (mean 56%; range 27–76%; p=0.09).
Predictors of CVD Risk Assessment and Treatment
In bivariate analyses of cumulative CVRF assessment (Table 4), formal transition was
associated with the largest increase in documented care (21%, p<0.001), followed by
transfer in 2006 or later (11% increase, p<0.01) and transplant recipient status (9% increase,
p=0.03). In multivariable analyses including gender, disease type, race/ethnicity, formal
transition and date of transfer, these associations persisted suggesting an independent
association with improved documentation of care (Table 4). When evaluating the composite
metric for recommended therapy, none of the patient-level factors were significantly
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associated in bivariate analyses (data not shown). In the multivariable model, transfer during
2006 or later was associated with an 11% increase in documented therapy for modifiable
CVRFs (p=0.03)
Discussion
The Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in
Children and Adolescents from the National Heart, Lung and Blood Institute recently
published its summary report indicating that children with CKD, ESRD or TXP are in the
highest risk tier for CVD and recommended specific CVRF assessment and preventive
therapy.[17] This study of adolescents with kidney disease transitioning to adult care
highlights the large gap that exists between clinical practice and recommended guidelines.
[5–13, 17] Recommended CVRF assessments and therapies were documented less than 60%
of the time and a small minority of patients received all components of recommended CVD
care. When evaluated, the burden of CVD risk-factors was high in this population, yet there
appears to be substantial variation in care both within and between centers. Together, these
results suggest that patients are not consistently receiving optimal preventive cardiology care
during adolescence, which may, in part, contribute to their exceedingly high risk of
cardiovascular death as adults.
The importance of CVD in adults who developed kidney disease in childhood is well
established. Parekh, et al. demonstrated that CVD is the leading cause of death in patients
with ESRD as children who died before the age of 30.[4] This is consistent with the high
prevalence of LVH, hypertension, dyslipidemia and other traditional CVRFs observed in the
present investigation and other studies[22–24] as well as the observation that the severity of
asymptomatic coronary and aortic atherosclerosis increases with the number of CVRFs.[18]
As such, CVD for children and adolescents with kidney disease has become a top priority
condition for clinical research[25] and a target for risk reduction through clinical practice
guidelines.[6–7, 9, 11–12, 17] Yet, despite these calls to action, current practice patterns
appear to be sub-optimal as only a small minority of patients in our study had a complete
assessment for traditional CVRFs. Even among those assessed and found to have modifiable
CVRF’s, all recommended therapy was prescribed in less than one-third.
Although suboptimal care has traditionally been attributed to a lack of vigilance by care
providers, it is more likely due to a lack of systems that optimize chronic disease care.[26]
Fifteen years ago Wagner and colleagues[27] identified that existing systems of care were
incapable of reliably delivering high-quality chronic disease management. In response, they
developed the Chronic Care Model[26] to help guide greater implementation of evidence-
based longitudinal care. Unfortunately, with the exception of relatively few care settings, the
Chronic Care Model has not been widely implemented in routine clinical practice and sub-
optimal chronic care spans across disciplines and populations.[28] From analysis of 175
quality metrics in more than 1500 children, Mangione-Smith, et al. observed that
recommended preventive care, screening and diagnosis were each documented less than half
of the time (41%, 38%, 47% respectively) and indicated therapy was documented only two-
thirds of the time.[14] In adult studies only 42–82% of hypertensive patients with CKD were
on medical therapy and only 20–60% of patients with CKD or a kidney transplant were
treated for uncontrolled cholesterol.[15–16] Together with our findings these studies suggest
that current systems of chronic disease management do not reliably provide optimal care. In
order to improve long-term outcomes, further research should explore system redesign as a
means to improve quality of care.[29]
One component of new, more reliable systems of care for adolescents transferring to adult
providers may be formal transition programs. Because of their emphasis on adult medical
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conditions and use of pathways and coordinated care, these programs have the potential to
improve care for high risk adolescents with chronic illness.[1, 30–35] Indeed, in their report
“Crossing the Quality Chasm: A New Health System for the 21st Century”[36] the Institute
of Medicine identified coordination of care as one of six key challenges for health system
redesign. Yet there is surprisingly little research evaluating the impact of transition programs
on clinical care.[1] In a recent systematic review, Crowley, et al. found only ten studies
across all chronic diseases that evaluated the impact of transition programs on medical
outcomes.[37] Of these, only one small, qualitative study included young people with
kidney disease.[38] Six of the other nine studies demonstrated positive impacts of formal
transition and two studies[39–40] in diabetes care specifically demonstrated improvements
in quality indicators among patients undergoing formal transition. A key finding of our
study is that formal transition was independently associated with a 21% increase in CVD
assessment, thus contributing to the small but growing literature that suggests formal
transition programs may have a favorable impact on quality of care.
Notably in our study, the center with the highest percentage of CVD assessments (86%) did
not report any formal transitions (Center E; Figures 1a and 2a). In contrast, the center
performing the most formal transitions (Center H) performed relatively few recommended
CVD assessments (49%). Thus, unmeasured contextual factors, such as other clinical
pathways, care preferences, priorities or presence of local experts, likely account for some
variation in quality of care between centers. Although, our data did not have measures of
these potential factors, our multilevel analysis allowed us to assess reported formal transition
as a predictor of CVD care controlling for study center- and patient-level characteristics and
partition variance into patient- and center-level variance. Despite considerable center-
specific variation, we found formal transition to be the strongest independent predictor of
improved CVD assessment in our population.
Both transplant status and transfer since 2006 were also associated with modest
improvements in CVD assessment. The reasons for improved care for transplant patients are
uncertain, but may be attributed to better adherence, greater use of protocols, more specific
guidelines,[5–6, 9] improved care coordination and/or other factors. Indeed some adult
literature suggests and inverse relationship between certain traditional CVRF’s and mortality
in adult dialysis patients,[19–20] whereas the same is not true for CKD or TXP patients.
Thus, providers may be more hesitant to monitor and treat dyslipidemia or obesity in
dialysis patients in comparison to those who have had a kidney transplant. Improved CVD
assessment after 2006 suggests more comprehensive care[6] or greater acceptance of
guidelines over time. Alternatively, greater adoption of electronic medical records may be
associated with improved documentation over time. Ultimately further research may
elucidate how and why these factors improve CVD care.
This is the largest cohort study of adolescents with kidney disease who have transferred
from pediatric to adult care and the only one, to our knowledge, that evaluates the quality of
CVD care in this high-risk population. Nonetheless, our findings must be interpreted in light
of several limitations. We sampled a diverse set of North American pediatric nephrology
programs, yet the centers who chose to participate may have been motivated by a particular
interest in optimizing CVD or transitional care. Thus, our results may overestimate the
percentage of recommended CVD care overall. Although wide variation in care was
observed, our sample has limited power to detect variations in care. The observed
prevalence of traditional CVRFs such as LVH may have been increased by detection bias.
We chose to focus this analysis only on traditional CVRF’s, whereas non-traditional
CVRF’s (e.g. inflammation, oxidative stress, abnormal mineral metabolism,
hyperhomocysteinemia, etc.) that may further impact cardiovascular outcomes in these
patients and should be the focus of future studies. Our study may underestimate treatment of
Hooper et al. Page 7













CVRF’s due to treatment approaches not recommended in the guidelines or captured in our
analysis, such as lowering steroid or calcinuerin inhibitor exposure for patients with elevated
fasting glucoses. Our analyses are based on retrospective chart reviews and are subject to
biases related to documentation. Thus, documentation of formal transition may be associated
with improved documentation of care, perhaps due to greater implementation of electronic
medical records over time, rather than improvements in actual care delivery. Indeed, this
may be one factor contributing to our observation that date of transfer after vs. before 2006
predicted improved CVD care. In addition, the components of transition programs at
participating facilities varied but were not characterized in sufficient detail to determine
whether more intensive or comprehensive programs were associated with better CVD care.
Finally, while this study provides important initial findings, additional research is needed to
assess the impact of patient-level characteristics, center-specific contextual factors, and
formal transitional programs on the quality of CVD care across other pediatric nephrology
centers. Nonetheless, this study provides important insight into current clinical practice and
the potential positive impact of transition programs.
Conclusion
In summary, we observed that when evaluated, adolescents with kidney disease have a large
burden of cardiovascular risk factors. These patients receive variable and sub-optimal
preventive CVD care that may contribute to their exceedingly high risk of subsequent
cardiovascular death in early adulthood. There is tremendous opportunity to lower this high
CVD burden and improve long-term cardiovascular outcomes for these patients and others
with chronic conditions by improving the reliability of preventive care. Formal transition
programs may be an important component of such new, more reliable, chronic care systems.
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The percentage of patients reported to go through a formal transition pathway at each of the
eight participating centers according to disease population: chronic kidney disease (CKD),
end-stage renal disease (ESRD), transplant (TXP). Note the marked within center (a) and
between center (b) variation of formal transition pathways for the different kidney disease
populations. The report of formal transition pathways varied across centers from 0 to 90% of
patients.
Hooper et al. Page 12














The percentage of patients who received each of five cardiovascular risk assessments before
transferring to adult care. Note the variation for each assessment within centers (a) and
between centers (b). On average 57% (range 44%–86%) of indicated assessment were
documented in each patients chart. Smoking status was the most commonly assessed
cardiovascular risk factor with 75% patients assessed, whereas less than 50% patients had a
fasting lipid profile or physical activity assessment.
Hooper et al. Page 13













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Pediatr Nephrol. Author manuscript; available in PMC 2014 June 01.
